Search

By Industry Solutions (2)
By Phase (1)
By Molecule Type (1)
By Therapeutic Area (3)
Covance Events (9)
Geography (3)
Keywords (10)

Filters

Showing results 33 - 48 of 91813 for .

Showing results 33 - 48 of 91813 for .

Best Practices and Solutions in the New Inflammation Paradigm
This profound shift in how inflammation is perceived and treated has led to escalating client interest, increased R activity, and explosive investment....
Identifying Challenges and Proposing Solutions in Conducting Alzheimer's Disease Clinical Trials
......for Alzheimer advances, Covance recently surveyed 100 of the most experienced investigators (throughout 25 countries) involved in Alzheimer's research
Study Links Selection of Preferred Central Lab to Investigator Satisfaction
Landmark study links overall clinical trial investigator satisfaction with sponsors' choice of Central Laboratory. ... the choice of a central lab can greatly affect a principal investigator's satisfaction level while conducting a clinical trial.
Unlocking Brain Tumor Biology: Covance's Genomics Laboratory and the Institute for Systems Biology Begin to Unravel the Genetic Mechanisms of Gliobastoma Multiforme
Covance's Seattle-based Genomics Laboratory (CGL) collaborated with the Institute for Systems Biology .... gene expression in Glioblastoma Multiforme (GBM),
Partnering for Success in Personalized Medicine: Central Labs and Companion Diagnostics
As the biopharmaceutical industry increasingly turns its focus to discovering and delivering targeted, personalized medications, the companion diagnostics field is rapidly advancing.
Why Some Sponsors are Considering Dedicated Resource Agreements
Dedicated Resource Agreements allow a CRO to serve as an extension of the sponsor's own team, instead of functioning as a separate entity.
Biotherapeutics and Immunogenicity Implications in Drug Development
immunogenicity rates discovered in preclinical studies do not necessarily preclude the initiation of clinical studies. Therefore, any new biotherapeutic....
Managing Drug Development Challenges for Inflammation Therapies
Inflammation plays a pivotal role in disease, providing multiple new targets for anti-inflammatory therapy. Traditionally, inflammatory diseases were addressed in a piecemeal
Enrichment Strategies for Phase I Oncology Clinical Trials
For Phase I oncology clinical trials, the primary objectives are to establish the safety of either a new drug or a new drug combination, to determine max...
Biosimilars Development Demands Expertise Across All Phases of Development
This is an exciting time for biosimilars. ...a recent MarketsandMarkets report, the global biosimilars market is expected to be worth $19.4 billion by 2014
Perfect (Storm) Performance: How Covance Central Laboratory Services Responded to Superstorm Sandy
Covance Central Laboratory Services was able to manage the risk to your trials and continue to deliver high data consistency during the onslaught of Hurricane Sandy
Unique Market Access Considerations for Small Biopharmas
As a small biopharma, you should begin developing a strong market access strategy at the end of your Phase I clinical trials.
Oncology Studies and the Shift to a Centralized Lab Approach
The industry is beginning to adopt the central lab approach for oncology studies. ...Oncology trials, use nearly every kind of test and specimen possible...
Biomarker Development and Disease Pathology in Modern Healthcare
Novel, collaborative approaches using biomarkers, assays and sampling, technology platforms, imaging and studies are key to effective drug development.
Addressing Operational Challenges in Conducting Clinical Trials [Infographic]
Over the last few years, clinical research departments have incurred worsening delays in conducting clinical trials. Nearly 80% of trials fail to meet milestones
CRO's Role in Supporting Companion Diagnostics
Companion diagnostics are at the core of a personalized medicine shift, helping provide more effective and efficient treatments in smaller # of patients.